Antigenics Inc. is Today's Focus Stock on MicroStockProfit.com


DALLAS, July 28, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Antigenics Inc. (Nasdaq:AGEN).  The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

Our trade alerts and ideas are provided free to investors.  Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.

The full report is available at: http://www.microstockprofit.com/lp/AGEN

AGEN is trading above its upper Bollinger Band.  Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.

Antigenics Inc. (AGEN) is a biotechnology company developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.  Oncophage has been tested in phase 3 clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in phase 1 and phase 2 clinical trials in a range of indications and is in phase 2 clinical trials in glioma, a type of brain cancer.  Its product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), which is used in numerous vaccines in third-party clinical trials as advanced as phase 3 for a variety of diseases, AG-707, a therapeutic vaccine program tested in a phase 1 clinical trial for the treatment of genital herpes, and Aroplatin, a liposomal chemotherapeutic tested in a phase 1 clinical trial for the treatment of solid malignancies and B-cell lymphomas.

Message Board Search for AGEN: http://www.boardcentral.com/boards/AGEN

In the report, the analyst notes:

"AGEN recently reported its results for the quarter ended March 31, 2010.  The Company reported a net loss attributable to common stockholders of $9.0 million, or $0.10 per share, basic and diluted, for the first quarter of 2010, compared with a net loss attributable to common stockholders in the first quarter of 2009 of $9.7 million, or $0.14 per share, basic and diluted.

"AGEN announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 (HSV-2), the virus that causes genital herpes, in infected patients.  Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells."

To read the entire report visit: http://www.microstockprofit.com/lp/AGEN

See what investors are saying about AGEN at penny stock forum

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities.  MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC.  Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication.  Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.



            

Contact Data